

## STATEMENT OF PURPOSE

RS28135 / S1017

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. This bill mirrors the federal Drug Enforcement Administration (DEA) controlled substance scheduling and descheduling decisions for 2020, including placing synthetic cannabinoids in Schedule I, an opiate in schedule II and another substance in Schedule V as well as one technical correction in Schedule IV.

## FISCAL NOTE

This legislation will have no fiscal impact to the General Fund or the Board of Pharmacy's dedicated fund. It has no fiscal impact because adding, removing, or rescheduling products to the Controlled Substances Act does not create any new state program and does not compel any state action.

### Contact:

Nicki Chopski  
Idaho Division of Occupational and Professional Licenses  
(208) 334-2356

**DISCLAIMER:** This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).